Controversies About COVID-19 and Anticancer Treatment with Immune Checkpoint Inhibitors
Melissa Bersanelli
Abstract
Since ICI can restore the immune-competence, if on one hand it can be paradoxically needed to develop the cytokine storm characterizing the acute respiratory distress syndrome (ARDS) phase, on the other hand the epidemiological features of SARS-CoV-2 infection lay for a lower probability to affect these patients compared with their chemo-treated immune-suppressed counterpart. "
Topics & Concepts
Coronavirus disease 2019 (COVID-19)Immune checkpointSevere acute respiratory syndrome coronavirus 2 (SARS-CoV-2)2019-20 coronavirus outbreakPD-L1MedicineNivolumabImmunologyImmunotherapyImmune systemVirologyDiseaseInternal medicineInfectious disease (medical specialty)OutbreakCancer Immunotherapy and BiomarkersCOVID-19 and healthcare impactsCOVID-19 Clinical Research Studies